PMC:7195088 / 16634-17093 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"659","span":{"begin":98,"end":106},"obj":"Species"},{"id":"748","span":{"begin":44,"end":63},"obj":"Chemical"},{"id":"749","span":{"begin":68,"end":79},"obj":"Chemical"},{"id":"750","span":{"begin":84,"end":94},"obj":"Chemical"},{"id":"912","span":{"begin":122,"end":140},"obj":"Disease"},{"id":"913","span":{"begin":248,"end":253},"obj":"Disease"},{"id":"914","span":{"begin":255,"end":260},"obj":"Disease"},{"id":"915","span":{"begin":328,"end":333},"obj":"Disease"},{"id":"916","span":{"begin":335,"end":340},"obj":"Disease"}],"attributes":[{"id":"A659","pred":"tao:has_database_id","subj":"659","obj":"Tax:9606"},{"id":"A748","pred":"tao:has_database_id","subj":"748","obj":"MESH:C558899"},{"id":"A749","pred":"tao:has_database_id","subj":"749","obj":"MESH:D053139"},{"id":"A750","pred":"tao:has_database_id","subj":"750","obj":"MESH:C086979"},{"id":"A912","pred":"tao:has_database_id","subj":"912","obj":"MESH:C000657245"},{"id":"A913","pred":"tao:has_database_id","subj":"913","obj":"MESH:D005334"},{"id":"A914","pred":"tao:has_database_id","subj":"914","obj":"MESH:D003371"},{"id":"A915","pred":"tao:has_database_id","subj":"915","obj":"MESH:D005334"},{"id":"A916","pred":"tao:has_database_id","subj":"916","obj":"MESH:D003371"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T8","span":{"begin":303,"end":307},"obj":"Body_part"},{"id":"T9","span":{"begin":383,"end":387},"obj":"Body_part"},{"id":"T10","span":{"begin":445,"end":449},"obj":"Body_part"}],"attributes":[{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A9","pred":"fma_id","subj":"T9","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A10","pred":"fma_id","subj":"T10","obj":"http://purl.org/sig/ont/fma/fma7195"}],"text":"Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T5","span":{"begin":303,"end":307},"obj":"Body_part"},{"id":"T6","span":{"begin":383,"end":387},"obj":"Body_part"},{"id":"T7","span":{"begin":445,"end":449},"obj":"Body_part"}],"attributes":[{"id":"A5","pred":"uberon_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A7","pred":"uberon_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"}],"text":"Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T16","span":{"begin":131,"end":140},"obj":"Phenotype"},{"id":"T17","span":{"begin":248,"end":253},"obj":"Phenotype"},{"id":"T18","span":{"begin":255,"end":260},"obj":"Phenotype"},{"id":"T19","span":{"begin":328,"end":333},"obj":"Phenotype"},{"id":"T20","span":{"begin":335,"end":340},"obj":"Phenotype"}],"attributes":[{"id":"A16","pred":"hp_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/HP_0002090"},{"id":"A17","pred":"hp_id","subj":"T17","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A18","pred":"hp_id","subj":"T18","obj":"http://purl.obolibrary.org/obo/HP_0012735"},{"id":"A19","pred":"hp_id","subj":"T19","obj":"http://purl.obolibrary.org/obo/HP_0001945"},{"id":"A20","pred":"hp_id","subj":"T20","obj":"http://purl.obolibrary.org/obo/HP_0012735"}],"text":"Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T81","span":{"begin":122,"end":130},"obj":"Disease"},{"id":"T82","span":{"begin":131,"end":140},"obj":"Disease"}],"attributes":[{"id":"A81","pred":"mondo_id","subj":"T81","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A82","pred":"mondo_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/MONDO_0005249"}],"text":"Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T71","span":{"begin":147,"end":152},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T72","span":{"begin":204,"end":205},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T73","span":{"begin":303,"end":307},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T74","span":{"begin":303,"end":307},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T75","span":{"begin":383,"end":387},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T76","span":{"begin":383,"end":387},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T77","span":{"begin":396,"end":402},"obj":"http://purl.obolibrary.org/obo/CLO_0001230"},{"id":"T78","span":{"begin":396,"end":402},"obj":"http://purl.obolibrary.org/obo/CLO_0037237"},{"id":"T79","span":{"begin":396,"end":402},"obj":"http://purl.obolibrary.org/obo/CLO_0050903"},{"id":"T80","span":{"begin":396,"end":402},"obj":"http://purl.obolibrary.org/obo/CLO_0054249"},{"id":"T81","span":{"begin":396,"end":402},"obj":"http://purl.obolibrary.org/obo/CLO_0054250"},{"id":"T82","span":{"begin":396,"end":402},"obj":"http://purl.obolibrary.org/obo/CLO_0054251"},{"id":"T83","span":{"begin":396,"end":402},"obj":"http://purl.obolibrary.org/obo/CLO_0054252"},{"id":"T84","span":{"begin":434,"end":435},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T85","span":{"begin":445,"end":449},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T86","span":{"begin":445,"end":449},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T118","span":{"begin":44,"end":63},"obj":"Chemical"},{"id":"T119","span":{"begin":44,"end":53},"obj":"Chemical"},{"id":"T120","span":{"begin":54,"end":63},"obj":"Chemical"},{"id":"T121","span":{"begin":68,"end":79},"obj":"Chemical"},{"id":"T122","span":{"begin":84,"end":94},"obj":"Chemical"},{"id":"T123","span":{"begin":147,"end":152},"obj":"Chemical"},{"id":"T124","span":{"begin":428,"end":430},"obj":"Chemical"}],"attributes":[{"id":"A118","pred":"chebi_id","subj":"T118","obj":"http://purl.obolibrary.org/obo/CHEBI_145924"},{"id":"A119","pred":"chebi_id","subj":"T119","obj":"http://purl.obolibrary.org/obo/CHEBI_31781"},{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_45409"},{"id":"A121","pred":"chebi_id","subj":"T121","obj":"http://purl.obolibrary.org/obo/CHEBI_7798"},{"id":"A122","pred":"chebi_id","subj":"T122","obj":"http://purl.obolibrary.org/obo/CHEBI_134730"},{"id":"A123","pred":"chebi_id","subj":"T123","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A124","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_16170"},{"id":"A125","pred":"chebi_id","subj":"T124","obj":"http://purl.obolibrary.org/obo/CHEBI_25195"}],"text":"Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery."}

{"project":"LitCovid-sentences","denotations":[{"id":"T109","span":{"begin":142,"end":183},"obj":"Sentence"},{"id":"T110","span":{"begin":184,"end":459},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Comparison of only supportive treatment vs. lopinavir/ritonavir vs. oseltamivir vs. umifenovir in patients with confirmed COVID-19 pneumonia. Open-label RCT (NCT04255017, recruiting). Primary endpoints: (a) rate of disease remission (mild disease: fever, cough and other symptoms relieved with improved lung CT; severe disease: fever, cough and other symptoms relieved with improved lung CT, Spo 2 \u003e 93% or Pao 2/Fio 2 \u003e 300 mm Hg); (b) time to lung recovery."}